Updating on Lighthouse Clinical Trial of ATSN-201 to Bring XLRS Patient Closer to Life-Changing Treatment
Time: 9:00 am
day: Conference Day Two
Details:
- Presenting the progress of Part B of the Lighthouse study to evaluate the subretinal injection of ATSN-201
- Illustrate the nature of AAV.SPR capsids to ensure safe delivery of AAV gene therapy
- Compare the success and challenges of Part B to Part A of phase II/III to optimize phase II/III trials and beyond
